专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009033831A1 MYOGLOBIN AS EARLY PREDICTOR OF MYOCARDIAL INFARCTION 审中-公开
标题翻译： MYOGLOBIN作为心肌梗塞早期预后因素
公开(公告)号：WO2009033831A1
公开(公告)日：2009-03-19
申请号：PCT/EP2008/056605
申请日：2008-05-29
申请人： F. HOFFMANN- LA ROCHE AG , ROCHE DIAGNOSTICS GMBH , HESS, Georg , HÜDIG, Hendrik , KIENTSCH-ENGEL, Rosemarie , ZDUNEK, Dietmar
发明人： HESS, Georg , HÜDIG, Hendrik , KIENTSCH-ENGEL, Rosemarie , ZDUNEK, Dietmar
IPC分类号： G01N33/68 , G01N33/92
CPC分类号： G01N33/6887 , G01N2333/805 , G01N2800/324
摘要： The present invention relates to a method for diagnosing myocardial infarction in a subject who suffers from acute coronary syndrome and has a cardiac Troponin level, which is detectable, but lower than the level that is considered as being indicative for a myocardial infarction. Moreover, the present invention relates to a method for identifying a subject being susceptible to cardiac intervention, wherein the subject suffers from acute coronary syndrome and has a cardiac Troponin level which is detectable, but lower than a level that is considered as being indicative for a myocardial infarction. The methods of the present invention are based on the determination of myoglobin and, optionally, Heart-type fatty acid binding protein (H-FABP) in a sample of said subject and comparing the amount of myoglobin and, optionally, H-FABP to reference amounts. Also comprised by the present invention are kits or devices to carry out the methods of the present invention.
摘要翻译：本发明涉及一种用于诊断患有急性冠状动脉综合征且具有心肌肌钙蛋白水平的受试者的心肌梗塞的方法，其可检测但低于被认为是指示心肌梗死的水平。此外，本发明涉及用于识别易受心脏干预的受试者的方法，其中所述受试者患有急性冠状动脉综合征，并且具有心脏肌钙蛋白水平，其可检测但低于被认为是指示心肌梗死本发明的方法是基于在所述受试者的样品中测定肌红蛋白和任选的心脏型脂肪酸结合蛋白（H-FABP），并将肌红蛋白和任选的H-FABP的量与参考金额。本发明还包括用于实施本发明方法的试剂盒或装置。

2. 发明申请

WO2012025355A1 USE OF BIOMARKERS IN THE ASSESSMENT OF THE EARLY TRANSITION FROM ARTERIAL HYPERTENSION TO HEART FAILURE 审中-公开
标题翻译：生物标记在评估从早期转移到心脏失效的早期转换中的应用
公开(公告)号：WO2012025355A1
公开(公告)日：2012-03-01
申请号：PCT/EP2011/063398
申请日：2011-08-03
申请人： ROCHE DIAGNOSTICS GMBH , F. HOFFMANN-LA ROCHE AG , WIENHUES-THELEN, Ursula-Henrike , BLOCK, Dirk , HÜDIG, Hendrik , VOGEL-ZIEBOLZ, Sabine , BÖHM, Christine , HESS, Georg , HORSCH, Andrea , ZDUNEK, Dietmar
发明人： WIENHUES-THELEN, Ursula-Henrike , BLOCK, Dirk , HÜDIG, Hendrik , VOGEL-ZIEBOLZ, Sabine , BÖHM, Christine , HESS, Georg , HORSCH, Andrea , ZDUNEK, Dietmar
IPC分类号： G01N33/53
CPC分类号： G01N33/54306 , G01N33/6887 , G01N33/6893 , G01N2333/4712 , G01N2333/495 , G01N2333/58 , G01N2800/325 , G01N2800/50 , G01N2800/52
摘要： The present invention relates to a method of diagnosing functional and/or structural abnormalities of the heart preceding heart failure, in a subject bearing risk factors of developing heart failure, the method comprising the steps of a) measuring in a sample obtained from the individual the concentration of at least one cardiac troponin, b) optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and c) assessing functional and/or a structural abnormalities by comparing the concentration determined in step (a) and optionally the concentration(s) determined in step (b) to the concentration of this marker or these markers as established in a control sample. The present invention also relates to a method of predicting the risk of a subject bearing risk factors of developing heart failure, to suffer from heart failure, the method comprising the steps of a) measuring in a sample obtained from the individual the concentration of at least one cardiac troponin, b) optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and c) predicting the risk of the subjects to suffer from heart failure by comparing the concentration determined in step (a) and optionally the concentration(s) determined in step (b) to the concentration of this marker or these markers as established in a control sample. The method, further characterized in that said one or more other marker is selected from the group consisting of a cardiac troponin marker, GDF 15 and insulin growth factor binding protein 7 (IGFBP7). In a preferred embodiment of the present invention, the subject suffers from left ventricular diastolic dysfunction. The present invention also relates to a method of deciding on the treatment of a subject bearing risk factors of developing heart failure and a method of monitoring the treatment. In preferred embodiments of the present invention, at least one further marker selected from: a cardiac troponin, GDF15 and IGFBP7. The present invention further relates to a method of monitoring treatment of functional and/or structural abnormalities of the heart preceding heart failure in a subject, the method comprising the steps of a) repeatedly determining, within given time intervals, the concentration of at least one cardiac troponin in at least one sample of said subject, b) optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and c) comparing the concentration determined in step (a) and optionally the concentration(s) determined in step (b) to the concentration of this marker or these markers as established in a control sample, and c) assessing, based on the differences in the determined concentrations in one or more of the above-cited markers, whether the subject has undergone a change in its pathophysiological state.
摘要翻译：本发明涉及诊断患有心力衰竭的心脏的功能和/或结构异常的方法，所述方法包括以下步骤：a）在从个体获得的样品中测量，至少一种心肌肌钙蛋白的浓度，b）任选地在样品中测量一种或多种其他心力衰竭标志物的浓度，和c）通过比较步骤（a）中测定的浓度来评估功能和/或结构异常）和任选地在步骤（b）中测定的浓度相对于在对照样品中确定的该标志物或这些标记物的浓度。本发明还涉及一种预测患有心力衰竭发生危险因素的受试者患有心力衰竭的风险的方法，所述方法包括以下步骤：a）在从个体获得的样品中测量至少至少一种心肌肌钙蛋白，b）任选地在样品中测量一种或多种其他心力衰竭标志物的浓度，以及c）通过比较步骤（a）中测定的浓度来预测受试者患有心力衰竭的风险，和任选的步骤（b）中测定的浓度与对照样品中确定的该标志物或这些标记物的浓度。该方法的特征还在于所述一种或多种其它标志物选自心肌肌钙蛋白标志物，GDF15和胰岛素生长因子结合蛋白7（IGFBP7）。在本发明的优选实施方案中，受试者患有左心室舒张功能障碍。本发明还涉及一种决定患有心脏衰竭发展危险因素的受试者的治疗方法和一种监测治疗方法。在本发明的优选实施方案中，至少一种选自以下的标记物：心肌肌钙蛋白，GDF15和IGFBP7。本发明还涉及一种监测受试者心脏衰竭前心脏的功能和/或结构异常的治疗方法，所述方法包括以下步骤：a）在给定的时间间隔内重复确定至少一个所述对象的至少一个样品中的心肌肌钙蛋白b）任选地在样品中测量一种或多种其它心力衰竭标志物的浓度，和c）将步骤（a）中测定的浓度和任选的浓度（（b）中测定的对照样品中确定的该标志物或这些标记物的浓度，以及c）基于一种或多种上述标记物中确定的浓度的差异来评估，受试者的病理生理状态发生变化。

3. 发明申请

WO2008145689A1 H-FABP AS EARLY PREDICTOR OF MYOCARDIAL INFARCTION 审中-公开
标题翻译： H-FABP作为心肌梗塞的早期预后因素
公开(公告)号：WO2008145689A1
公开(公告)日：2008-12-04
申请号：PCT/EP2008/056603
申请日：2008-05-29
申请人： F. HOFFMANN LA-ROCHE AG , ROCHE DIAGNOSTICS GMBH , HESS, Georg , HÜDIG, Hendrik , KIENTSCH-ENGEL, Rosemarie , ZDUNEK, Dietmar
发明人： HESS, Georg , HÜDIG, Hendrik , KIENTSCH-ENGEL, Rosemarie , ZDUNEK, Dietmar
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N2800/324
摘要： The present invention relates to a method for diagnosing myocardial infarction in a subject who suffers from acute coronary syndrome and has a cardiac Troponin level, which is detectable, but lower than the level that is considered as being indicative for a myocardial infarction. Moreover, the present invention relates to a method for identifying a subject being susceptible to cardiac intervention, wherein the subject suffers from acute coronary syndrome and has a cardiac Troponin level which is detectable, but lower than a level that is considered as being indicative for a myocardial infarction. The methods of the present invention are based on the determination of H-FABP and, optionally, myoglobin in a sample of said subject and comparing the amount of H-FABP and, optionally, myoglobin to reference amounts. Also comprised by the present invention are kits or devices to carry out the methods of the present invention.
摘要翻译：本发明涉及一种用于诊断患有急性冠状动脉综合征且具有心肌肌钙蛋白水平的受试者的心肌梗塞的方法，其可检测但低于被认为是指示心肌梗死的水平。此外，本发明涉及用于识别易受心脏干预的受试者的方法，其中所述受试者患有急性冠状动脉综合征，并且具有心脏肌钙蛋白水平，其可检测但低于被认为是指示心肌梗死本发明的方法是基于所述受试者的样品中H-FABP和任选的肌红蛋白的测定，并将H-FABP和任选的肌红蛋白的量与参考量进行比较。本发明还包括用于实施本发明方法的试剂盒或装置。

4. 发明申请

WO2008142110A1 MEANS AND METHODS FOR ASSESSING HEART FAILURE IN PATIENTS WITH ATRIAL FIBRILLATION USING GDF-15 AND NATRIURETIC PEPTIDES 审中-公开
标题翻译：使用GDF-15和NATRIURETIC PEPTID评估患有ATRIAL FIBRILLATION患者心脏失效的手段和方法
公开(公告)号：WO2008142110A1
公开(公告)日：2008-11-27
申请号：PCT/EP2008/056261
申请日：2008-05-21
申请人： ROCHE DIAGNOSTICS GMBH , F. HOFFMANN-LA ROCHE AG , HESS, Georg , HORSCH, Andrea , HÜDIG, Hendrik , ZDUNKEK, Dietmar
发明人： HESS, Georg , HORSCH, Andrea , HÜDIG, Hendrik , ZDUNKEK, Dietmar
IPC分类号： G01N33/68
CPC分类号： G01N33/6863 , G01N33/74 , G01N2333/495 , G01N2333/58 , G01N2800/324 , G01N2800/325
摘要： The present invention is concerned with methods and devices for medical diagnosis. Specifically, it relates to a method of diagnosing heart failure in a subject exhibiting atrial fibrillation, said method comprising determining the amount of GDF-15 in a sample of said subject and comparing the said amount of GDF-15 witha suitable reference amount whereby heart failure is to be diagnosed. Moreover, the present invention relates to a diagnostic device and a kit for carrying out the aforementioned method.
摘要翻译：本发明涉及用于医学诊断的方法和装置。具体地说，本发明涉及诊断呈现心房颤动的受试者的心力衰竭的方法，所述方法包括确定所述受试者样品中GDF-15的量，并将所述GDF-15的量与合适的参考量进行比较，从而使心力衰竭被诊断。此外，本发明涉及一种用于执行上述方法的诊断装置和套件。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式